Mesoblast Data Highlights Critical Need for Early Ryoncil Use in Severe GvHD
Event summary
- Mesoblast presented data at the February 2026 Tandem Meetings showing Ryoncil achieved high survival rates in SR-aGvHD patients regardless of age or treatment line.
- 15% mortality rate before completing Ryoncil treatment in third-line use vs. 2% in second-line, emphasizing early intervention benefits.
- Adult patients in EIND program showed comparable survival to children, supporting planned pivotal trial for adult SR-aGvHD.
- Pivotal trial for adults expected to begin enrollment this quarter, potentially tripling Ryoncil's addressable market.
The big picture
Mesoblast's data reinforces the strategic importance of early intervention in severe GvHD, positioning Ryoncil as a potential standard of care. The planned adult trial represents a significant market opportunity, potentially tripling Ryoncil's addressable population. Success could solidify Mesoblast's leadership in cellular therapies for inflammatory diseases.
What we're watching
- Trial Timing
- Whether Mesoblast can initiate its adult SR-aGvHD trial as planned this quarter and secure IRB approval.
- Market Expansion
- The pace at which Ryoncil gains approval for adult use and captures the larger adult SR-aGvHD market.
- Competitive Positioning
- How early intervention data will position Ryoncil against emerging therapies for severe GvHD.
Our editorial coverage:
Related topics